[Antiviral properties of recombinant human lymphotoxin].
Study of the antiviral properties of recombinant human lymphotoxin obtained from Escherichia coli SG20050/pLT21 strain by microbiological synthesis showed this lymphotoxin to inhibit vesicular stomatitis virus on M-19 cells and exert a synergistic effect with recombinant human gamma-interferon. The drug exhibited no anti-HIV1 activity in experiments with MT4 cells pretreated with the virus or the drug itself; on the contrary, HIV1 reproduction in these cells was enhanced at low concentrations of the recombinant lymphotoxin.
Denisov
A A
AA
Nikolaeva
O G
OG
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D003001:Cloning, Molecular; D004357:Drug Synergism; D004926:Escherichia coli / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D008233:Lymphotoxin-alpha / Q000235:genetics / Q000494:pharmacology*; D051379:Mice; D011994:Recombinant Proteins / Q000235:genetics / Q000494:pharmacology; D014721:Vesicular stomatitis Indiana virus / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D008233:Lymphotoxin-alpha; D011994:Recombinant Proteins; D007371:Interferon-gamma
Protivovirusnye svoĭstva rekombinantnogo limfotoksina cheloveka.